TriSalus Life Sciences, Inc. (TLSI) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 5.08 at 3:45 pm ET, low 4.77 at 4:45 am ET.
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
the bull case· 2
79
managers reporting a position in thirteen f filings
13fJun 30 '26+27.54%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 4
3
of the funds on file reporting a position in TLSI
n-portas of Jun 30 '260.01%
of iShares Russell two thousand ETF's assets the largest fund weight on file
n-portJun 30 '2611
managers whose positions together make up four fifths of reported value
13fJun 30 '264 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 13 '26 report. Not a forecast, not advice.
Of the 4 companies TriSalus Life Sciences, Inc. moves with most closely, none share its SEC classification.
Measured against 178 trading days of our own closes. Co-movement, not cause.
SIC 3841, Surgical & Medical Instruments & Apparatus, from each company's own filings. Largest first.
78 managers report a position worth $99.0M between them, and 11 of them hold 80% of it.
tall tick = annual report · 1 on record
TriSalus Life Sciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Surgical & Medical Instruments & Apparatus
TLSI (TriSalus Life Sciences, Inc.) has 2 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.